What a VA Study Found About Intravenous Ketamine for Depression

Important: Compounded ketamine is not FDA-approved. FDA has not evaluated its safety, effectiveness, or quality before marketing. Ketamine injection is approved for anesthesia, not psychiatric conditions. Compounded ketamine nasal spray is different from FDA-approved Spravato (esketamine), and research on other formulations or treatment settings does not establish its benefits.

A research headline is most useful when the numbers, treatment setting, and limitations stay visible. A study of veterans receiving ketamine offers an example of why the original report matters.

The study and its actual findings

The 2024 study in the Journal of Clinical Psychiatry reviewed Veterans Health Administration records for 215 patients receiving intravenous ketamine for depression. At six weeks, 26% met the study’s response threshold of a 50% improvement in PHQ-9 score; 15% met its remission threshold. These are different outcomes and should not be described as a universal success rate.

The report found that improvements seen early were sustained in the observed sample over at least six months, with continued infusions and decreasing frequency. The authors called for further research on infusion frequency and adverse effects with repeated treatment.

Why the design matters

This was a review of care delivered in practice, not a randomized comparison with another treatment. Its findings describe the patients and care captured in those records. They cannot establish how an individual would respond or prove that ketamine was better than another available option.

Response means a specified amount of improvement on a symptom scale. Remission means reaching a low symptom score under the study’s definition. Neither term guarantees permanent recovery, and someone may still need ongoing care or support. For a broader checklist of questions about these numbers, see how to interpret ketamine response percentages.

What it does not tell us about nasal spray

The intervention was intravenous ketamine. The study did not evaluate a compounded nasal spray used at home or a ketamine combination containing additional ingredients. Its outcome percentages cannot be transferred to those products. Treatment setting is also important when assessing how adverse effects are monitored and managed.

Using the evidence in an appointment

Ask your clinician how closely a cited study matches the medication, diagnosis, and care setting being proposed. Ask what outcomes you will track, when you will review them, and what happens if benefit is limited.

A careful discussion should include the people who did not meet response thresholds. Research can inform shared decisions without becoming a promise or a testimonial for a different treatment.

Safety and the treatment setting

Ketamine can cause sedation, dissociation, impaired thinking or coordination, nausea, increased blood pressure or heart rate, and slowed breathing. Abuse or misuse, worsening psychiatric symptoms, and urinary or bladder problems are also concerns. This is not a complete list of risks.

At home, a healthcare professional is not onsite to monitor you or respond immediately to an adverse reaction. Telehealth support does not provide the same monitoring as an onsite care team. Review these FDA ketamine risk alerts and discuss your health history, other medications, monitoring needs, and emergency plan with your clinician.

Discuss your options

Bliss Mist Rx LLC provides telehealth services; we do not manufacture or compound medication. If a clinician prescribes treatment, an independent, appropriately licensed compounding pharmacy dispenses it. A consultation does not guarantee a prescription or a particular outcome. Book a Free Virtual Appointment or Follow-Up to discuss questions about your care.

This article is general education and does not replace individualized medical advice.